中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非酒精性脂肪性肝病无创性诊断方程的构建

冯巩 韩海静 齐雪 弥曼 田秋梅 牛春燕

引用本文:
Citation:

非酒精性脂肪性肝病无创性诊断方程的构建

DOI: 10.3969/j.issn.1001-5256.2018.06.026
基金项目: 

陕西省普通高等学校优势学科建设项目(陕教位[2014]3号文件); 

详细信息
  • 中图分类号: R575.5

Establishment of a noninvasive diagnosis equation for nonalcoholic fatty liver disease

Research funding: 

 

  • 摘要:

    目的利用与非酒精性脂肪性肝病(NAFLD)相关的常用临床及实验室指标,构建无创性诊断方程,并评估该方程对NAFLD的预测及诊断价值。方法选取2016年11月-2017年11月西安医学院第一附属医院诊断为NAFLD患者127例和健康对照者30例,记录研究对象的性别、年龄、BMI、病史、ALT、AST、GGT、尿素氮(BUN)、尿酸(UA)、血肌酐(Cr)、TC、TG、HDL、LDL、糖化血红蛋白(HBA1c)、游离脂肪酸(FFA)、空腹血糖(FPG)、空腹胰岛素(FINS)、PLT、超声检查结果和Fibro Scan的检查结果等数据。计量资料组间比较采用t检验,相关性使用Pearson相关性分析,回归方程的构建使用多元线性回归方程模型,构建受试者工作特征曲线(ROC曲线),计算回归方程的敏感度和特异度。结果与脂肪肝相关的指标包括BMI(r=0.308,P=0.005)、ALT(r=0.379,P<0.001)、AST(r=0.318,P=0.004)、GGT(r=0.293,P=0.009)、UA(r=0.244,P=0.033)、FFA(r=0.249,P=0.030);对Fib...

     

  • [1]LOOMBA R.Role of imaging-based biomarkers in NAFLD:recent advances in clinical application and future research directions[J].J Hepatol, 2018, 68 (2) :296-304.
    [2]HARDY T, OAKLEY F, ANSTEE QM, et al.Nonalcoholic fatty liver disease:Pathogenesis and disease spectrum[J].Annu Rev Pathol, 2016, 11 (1) :451-496.
    [3]COBBINA E, AKHLAGHI F.Non-alcoholic fatty liver disease (NAFLD) -pathogenesis, classification, and effect on drug metabolizing enzymes and transporters[J].Drug Metab Rev, 2017, 49 (2) :197.
    [4]CHARYTONIUK T, DRYGALSKI K, KONSTANTYNOWICZNOWICKA K, et al.Alternative treatment methods attenuate the development of NAFLD:A review of resveratrol molecular mechanisms and clinical trials[J].Nutrition, 2017, 34:108-117.
    [5]FENG G, NIU CY.Advances in the treatment of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2017, 33 (12) :2433-2438. (in Chinese) 冯巩, 牛春燕.非酒精性脂肪性肝病的治疗进展[J].临床肝胆病杂志, 2017, 33 (12) :2433-2438.
    [6]SUMIDA Y, NAKAJIMA A, ITOH Y.Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].World J Gastroenterol, 2014, 20 (2) :475-485.
    [7]Fatty liver and alcoholic liver disease group of the Chinese Medical Association for Hepatology.Guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease (Revised Edition 2010) [J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南 (2010年修订版) [J].临床肝胆病杂志, 2010, 26 (2) :120-124.
    [8]LDINGHEN VD, WONG GL, VERGNIOL J, et al.Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease[J].J Gastroenterol Hepatol, 2016, 31 (4) :848-855.
    [9]TAPPER EB, CASTERA L, AFDHAL NH.Fibro Scan (vibrationcontrolled transient elastography) :Where does it stand in the united states practice[J].Clin Gastroenterol Hepatol, 2015, 13 (1) :27-36.
    [10]WONG VW, CHAN WK, CHITTURI S, et al.The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017Part 1:Definition, risk factors and assessment[J].J Gastroenterol Hepatol, 2018, 33 (1) :70-85.
    [11]ZHANG SS, LI JX.Consensus opinion of experts on diagnosis and treatment of non-alcoholic fatty liver disease (2017) [J].J Tradit Chin Med, 2017, 58 (19) :1706-1710. (in Chinese) 张声生, 李军祥.非酒精性脂肪性肝病中医诊疗专家共识意见 (2017) [J].中医杂志, 2017, 58 (19) :1706-1710.
    [12]BEDOGNI G, BELLENTANI S, MIGLIOLI L, et al.The Fatty Liver Index:A simple and accurate predictor of hepatic steatosis in the general population[J].BMC Gastroenterol, 2006, 6:33.
    [13]KOTRONEN A, PELTONEN M, HAKKARAINEN A, et al.Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors[J].Gastroenterology, 2009, 137 (3) :865.
    [14]BRUNT EM, WONG VW, NOBILI V, et al.Nonalcoholic fatty liver disease[J].Nature Reviews Disease Primers, 2015, 1:15080.
  • 加载中
计量
  • 文章访问数:  2039
  • HTML全文浏览量:  69
  • PDF下载量:  369
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-02-06
  • 出版日期:  2018-06-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回